Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EMD 72000

Known as: EMD-72000, EMD72000 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

matuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma.
Epidermal growth factor receptor (EGFR) imaging in brain tumors is essential to visualize overexpression of EGFRvIII variants as… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
An increasing number of therapeutic antibodies targeting tumors that express the epidermal growth factor receptor (EGFR) are in… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2008
2008
Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk
Molecular inhibition of the epidermal growth factor receptor (EGFR) is a promising anticancer strategy, and monoclonal antibodies… Expand
2008
2008
Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine
Purpose: The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2007
Highly Cited
2007
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.
OBJECTIVE The primary objective of this study was to determine the rate of response to matuzumab in patients with recurrent, EGFR… Expand
2005
2005
Magnetic resonance imaging in an orthotopic rat model: Blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth
The purpose of our research was to investigate the antiangiogenic effect of the epidermal growth factor receptor monoclonal… Expand
2005
2005
A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Mullerian malignancies
3151 Background: A high proportion of ovarian tumors express the epidermal growth factor receptor (EGFR). Preclinical and… Expand
2005
2005
A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK…
3077 Background: Matuzumab is a humanized monoclonal antibody binding to the EGFR with higher affinity than natural ligands (eg… Expand
Highly Cited
2004
Highly Cited
2004
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
PURPOSE To investigate the safety and tolerability and to explore the pharmacokinetic and pharmacodynamic profile of the… Expand
2004
2004
Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer.
3061 Background: Monoclonal antibody EMD 72000 blocks ligand binding and inhibits EGFR activation and signal transduction. EGFR… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE